Evidence map›Paper›PMID 35641031›Full record

ArticleJournal of pharmacological sciences2022

Antiviral activity of ciclesonide acetal derivatives blocking SARS-CoV-2 RNA replication.

Genichiro Tsuji, Shogo Nakajima, Koichi Watashi, Shiho Torii, Rigel Suzuki, Takasuke Fukuhara, Nobumichi Ohoka, Takao Inoue, Yosuke Demizu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of pharmacological sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Genichiro TsujiDivision of Organic Chemistry, National Institute of Health Sciences, 3-25-26 Tonomachi, Kawasaki-ku, Kawasaki, Kanagawa, 210-9501, Japan. Electronic address: gtsuji@nihs.go.jp.
Shogo NakajimaNational Institute of Infectious Diseases, Research Center for Drug and Vaccine Development, 1-23-1 Toyama, Shinjuku-ku, Tokyo, 162-8640, Japan; National Institute of Infectious Diseases, Department of Virology II, 1-23-1 Toyama, Shinjuku-ku, Tokyo, 162-8640, Japan; Choju Medical Institute, 19-14 Yamanaka, Noyoricho, Toyohashi, Aichi, 441-8124, Japan.
Koichi WatashiNational Institute of Infectious Diseases, Research Center for Drug and Vaccine Development, 1-23-1 Toyama, Shinjuku-ku, Tokyo, 162-8640, Japan; National Institute of Infectious Diseases, Department of Virology II, 1-23-1 Toyama, Shinjuku-ku, Tokyo, 162-8640, Japan; Department of Applied Biological Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, 278-8510, Japan.
Shiho ToriiLaboratory of Virus Control, Research Institute for Microbial Diseases, Osaka University, Suita, 565-0871, Japan; Insect-Virus Interactions Unit, Department of Virology, Institute Pasteur, Paris, 75015, France.
Rigel SuzukiDepartment of Microbiology and Immunology, Graduate School of Medicine, Hokkaido University, N-15, W-7, Kita-ku, Sapporo, Hokkaido, 060-8638, Japan.
Takasuke FukuharaDepartment of Microbiology and Immunology, Graduate School of Medicine, Hokkaido University, N-15, W-7, Kita-ku, Sapporo, Hokkaido, 060-8638, Japan.
Nobumichi OhokaDivision of Molecular Target and Gene Therapy Products, National Institute of Health Sciences, 3-25-26 Tonomachi, Kawasaki-ku, Kawasaki, Kanagawa, 210-9501, Japan.
Takao InoueDivision of Molecular Target and Gene Therapy Products, National Institute of Health Sciences, 3-25-26 Tonomachi, Kawasaki-ku, Kawasaki, Kanagawa, 210-9501, Japan.
Yosuke DemizuDivision of Organic Chemistry, National Institute of Health Sciences, 3-25-26 Tonomachi, Kawasaki-ku, Kawasaki, Kanagawa, 210-9501, Japan; Graduate School of Medical Life Science, Yokohama City University, 1-7-29, Yokohama, Kanagawa, 230-0045, Japan. Electronic address: demizu@nihs.go.jp.
National Institute of Health Sciences · JPHokkaido University · JPInstitut Pasteur · FRNational Institute of Infectious Diseases · JPTokyo University of Science · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ciclesonide (Cic) is approved as an inhalant for asthma and was clinically tested as a candidate therapy for coronavirus disease 2019 (COVID-19). Its active metabolite Cic2 was recently reported to suppress genomic RNA replication of severe acute respiratory syndrome coronavirus 2. In this study, we designed and synthesized a set of ciclesonide-acetal (Cic-acetal) derivatives. Among designated compounds, some Cic-acetal derivatives with a linear alkyl chain exhibited strong viral copy-number reduction activities compared with Cic2. These compounds might serve as lead compounds for developing novel anti-COVID-19 agents.

Indexed as

Antiviral AgentsCOVID-19 Drug TreatmentAcetalsHumansPregnenedionesRNA, ViralSARS-CoV-2Virus ReplicationAcetalsAntiviral AgentsciclesonidePregnenedionesRNA, ViralAntiviral activityCiclesonideSARS-CoV2

Identifiers

PMID35641031
PMCPMC9014634
OpenAlexW4224069322

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.